Dapson in acne vulgaris

Phase 2

• Conditions: Acne vulgaris.; Acne vulgaris; L70.0

• Registration Number: IRCT2017072035195N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with acne vulgaris who have 15-50 inflammatory lesions and 20-100 non-inflammatory lesions (comedones) (ranked as moderate in the GASS classification).
The total number of lesions accounts for 30 to 120 (ranked as moderate in the GASS classification).

Exclusion Criteria

Secondary acne due to other diseases or causes
Using other oral or topical medicines to treat acne
G6PD deficiency
Severe nodular cystic acne (ranked as very severe in the GASS classification)
Acne conglobata.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Inflammatory lesion (papule & pustule) non inflammatory (comedone). Timepoint: weeks 2, 4, 8, 12 after treatment. Method of measurement: GAAS Score.

Secondary Outcome Measures

Name	Time	Method
Side effects (Erythem, Burning, pruritus, Skin dryness, phototoxicity). Timepoint: weeks 2 , 4 , 8 , 12 after treatment. Method of measurement: History and examination.